SG Americas Securities LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO

SG Americas Securities LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 48.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,178 shares of the biopharmaceutical company’s stock after selling 16,915 shares during the period. SG Americas Securities LLC’s holdings in Halozyme Therapeutics were worth $1,175,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC lifted its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Harbour Investments Inc. grew its holdings in Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares in the last quarter. Clearstead Advisors LLC increased its stake in Halozyme Therapeutics by 64.8% in the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP bought a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,030,564.60. This represents a 1.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,179 shares of company stock worth $5,687,400 over the last three months. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $79.45 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $53.33 and a 1 year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The stock’s 50 day simple moving average is $69.41 and its two-hundred day simple moving average is $69.42. The company has a market cap of $9.42 billion, a PE ratio of 28.58, a price-to-earnings-growth ratio of 0.33 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.